Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …

Tuberculosis remains the world's leading cause of death from an infectious disease,
responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of …

Background Information on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) is
still limited. The aim of this study was to describe the features of the TB/COVID-19 co …

Background: The American Thoracic Society, US Centers for Disease Control and
Prevention, European Respiratory Society, and Infectious Diseases Society of America …

Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …

A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

Background Bedaquiline improves outcomes of patients with rifampicin-resistant and
multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this …

The World Health Organization (WHO) recommends that countries implement
pharmacovigilance and collect information on active drug safety monitoring (aDSM) and …

Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease.
With growing drug resistance the epidemic remains and will require significant attention and …